Staff
Enveric Biosciences (NASDAQ: ENVB), a neuroscience company developing next-generation, psychedelic-inspired mental health medicines, announces yet another filing of a provisional patent application based on new discoveries by the Company. This adds to their”Psybrary”.
The application describes more than 100 novel individual molecules and, if the broadest claims are allowed, could protect more than 10,000 possible new drug development candidates. The patent application and claimed drug candidates fall into the Company’s EVM201 second-generation, psychedelic-derived drug development program, with an initial target indication of cancer-related distress (CRD) and the potential to be expanded into additional mental health indications.
Dr. Peter Facchini, Ph.D., Chief Innovation Officer at Enveric, noted, “Our proprietary PsyAI artificial intelligence technology was used to design and provisionally rank a large and diverse collection of psychedelic-inspired molecules for further development. The majority of these new molecules, all of which are protected by this most recent provisional patent application, have already been synthesized in quantities sufficient to evaluate their safety and pharmacological properties, including receptor-binding profiles and behavioral analyses in animals. Based on our extensive in silico and experimental data, we are hopeful that we can nominate our lead candidates for entry into Enveric’s EVM201 preclinical development later this year.”
